FDA Cuts Prompt Biotech Players To Rethink Deal Strategies

Funding cuts at the U.S. Department of Health and Human Services are sending ripples of concern through the biotech industry, as attorneys advise companies to consider a wider breadth of strategic...

Already a subscriber? Click here to view full article